All In Biotech

Drug Trial Radar · NCT02200614

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,509 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,509

Actual

Start

Sep 12, 2014

Primary completion

Sep 3, 2018

Study completion Jun 14, 2021

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Jul 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Conditions

  • Prostate Cancer Non-Metastatic
  • Castration-Resistant

Interventions

  • Darolutamide (Nubeqa, BAY1841788)Drug

    Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.

  • PlaceboDrug

    Matching placebo 2 tablets twice daily with food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Metastasis-Free SurvivalTime frame: From randomization to the time approximately 385 MFS events were observed (approximately 48 months)

Locations

404 sites in 36 countries. Site status is shown where the registry gives one.

  • Site not named

    Homewood, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Tucson, Arizona

  • Site not named

    Fountain Valley, California

  • Site not named

    La Jolla, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Parker, Colorado

  • Site not named

    Boca Raton, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Saint Lucie, Florida

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Evanston, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Greenwood, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Wichita, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Annapolis, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Salisbury, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Royal Oak, Michigan

  • Site not named

    Omaha, Nebraska

  • Site not named

    Omaha, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Voorhees Township, New Jersey

  • Site not named

    Syracuse, New York

  • Site not named

    The Bronx, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Asheboro, North Carolina

Showing 40 of 404 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.